Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth differentiation factor 15 (GDF15) is a strong predictor of cardiovascular events and mortality in individuals with or without cardiovascular diseases.
|
28806401 |
2017 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Circulating GDF-15 levels predict future secondary manifestations of cardiovascular disease explicitly in women but not men with atherosclerosis.
|
28389123 |
2017 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased levels of growth differentiation factor-15 (GDF15) are associated with cachexia, cardiovascular disease and all-cause mortality.
|
28298399 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, little is known about the function of GDF-15 in cardiovascular disease, and the underlying regulatory network of GDF-15 is not known.
|
26681806 |
2016 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Neuregulin-1(NRG-1) has now been accepted to have therapeutic potential in cardiovascular disease.
|
26902151 |
2016 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GDF-15 is not only involved in cancer development, progression, angiogenesis and metastasis, but also controls stress responses, bone formation, hematopoietic development, adipose tissue function and cardiovascular diseases.
|
25690161 |
2015 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
GDF15 (rs1058587) does not influence the development of CVD in the population studied.
|
26090487 |
2015 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth differentiation factor 15 (GDF15) is an independent predictor of cardiovascular disease, and increased GDF15 levels have been associated with endothelial dysfunction in selected patients.
|
23262134 |
2013 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth-differentiation factor-15 level may be used as a biomarker of anthracycline-induced cardiovascular disease severity in the CCS.
|
23850849 |
2013 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytokine growth differentiation factor-15 (GDF-15), a member of the TGF beta superfamily, has recently been discovered to play an important role in cardiovascular diseases.
|
23800095 |
2013 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth differentiation factor 15 (GDF15) is emerging as valuable biomarker in cardiovascular disease and diabetic kidney disease.
|
23986522 |
2013 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Polymorphisms of the genes encoding CD40 and growth differentiation factor 15 and in the 9p21.3 region in patients with rheumatoid arthritis and cardiovascular disease.
|
22505696 |
2012 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasma GDF15 concentrations were measured in 2991 participants in the Framingham Offspring Study who were free of clinically overt CVD (mean age, 59 years; 56% women).
|
22997280 |
2012 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth differentiation factor (GDF)-15 belongs to a member of the transforming growth factor-β cytokine superfamily, and elevated GDF-15 concentrations are linked to increased risk of cardiovascular diseases and future adverse cardiac events in apparently healthy elderly women, acute coronary syndrome, and chronic heart failure.
|
21312063 |
2011 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GDF-15 has great potential as a biomarker in cardiovascular diseases, especially for prognosis, and is seen as a myocardial protective cytokine, but the exact mechanism of GDF-15 in cardiovascular diseases remains unknown.
|
21718220 |
2011 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We explored GDF-15 in preeclampsia and in diabetic pregnancies, because these conditions are associated with augmented risk for cardiovascular disease, both in mother and in offspring.
|
19470878 |
2009 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Of these women, we established baseline concentrations of MIC-1 in 257 who subsequently had myocardial infarction, stroke, or died from a cardiovascular event (cases) and in 257 matched for age and smoking status, who did not report cardiovascular disease during 4-year follow-up (controls).
|
12090982 |
2002 |